[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autologous-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autologous-stem-cell-transplantation":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100145560","cibmtr-research-database-100145560",false,"NCT01166009","CIBMTR Research Database","Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","Eligibility to Participate in the Research Database\n\nRecipient Eligibility Criteria:\n\n* Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children.\n\nIndividual with Marrow Toxic Injury Eligibility Criteria:\n\n* Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.\n\nUnrelated Donor Eligibility Criteria:\n\n* All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database.\n* All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.","ALL",{"count":18,"type":19},99999999,"ESTIMATED","OBSERVATIONAL","The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.\n\nA secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.\n\nObjectives:\n\nTo learn more about what makes stem cell transplants and cellular therapies work well such as:\n\n* Determine how well recipients recover from their transplants or cellular therapy;\n* Determine how recovery after a transplant or cellular therapy can be improved;\n* Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;\n* Determine how access to transplant or cellular therapy for different groups of patients can be improved;\n* Determine how well donors recover from the collection procedures.",[23,24,25,26,27,28,29],"Autologous Stem Cell Transplantation","Allogeneic Stem Cell Transplantation","Solid Tumors","Blood Cancers","CAR-T","Gene Therapy","Non-malignant Disease",[31,32,33,34,28,27],"Data Collection","CIBMTR","NMDP","Stem Cell Transplantation","RECRUITING","2025-08-07",{"date":38,"type":39},"2025-08-12","ACTUAL",{"date":41,"type":4},"2002-07",{"date":43,"type":19},"2050-07",{"name":45,"class":46},"Center for International Blood and Marrow Transplant Research","NETWORK",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100561303","phase-3-olanzapine-25-vs-5-mg-in-quadruplet-nauseavomiting-prophylaxis-before-high-dose-melphalan-100561303","NCT06588413","Olanzapine 2.5 vs 5 mg in Quadruplet Nausea\u002FVomiting Prophylaxis Before High-Dose Melphalan","Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 mg Versus 5 mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: The FONDO-LOW Study","FONDO-LOW","Inclusion Criteria:\n\n* Receipt of high-dose melphalan 140-200 mg\u002Fm2\n* Autologous stem cell transplantation recipient\n\nExclusion Criteria:\n\n* Allergy to olanzapine\n* Documented nausea or vomiting within 24 hours prior to enrollment\n* Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy\n* Chronic alcoholism\n* Pregnant\n* Decline or unable to provide informed consent","18 Years",{"count":58,"type":19},172,"INTERVENTIONAL",[61],"PHASE3","Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea\u002Fvomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea\u002Fvomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.",[64,23],"Multiple Myeloma",[66,67,68,69,70],"CINV","Nausea","Olanzapine","Melphalan","autologous transplant","2024-11-20",{"date":73,"type":39},"2024-11-22",{"date":75,"type":39},"2024-09-17",{"date":77,"type":19},"2027-10",{"name":79,"class":80},"Augusta University","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":81},"100433157","protocol-for-a-research-sample-repository-for-hematopoietic-cell-transplantation-other-cellular-therapies-and-marrow-toxic-injuries-100433157","NCT04920474","Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","Eligibility to participate in the Research Sample Repository Protocol:\n\nHematopoietic Cell (HC) or Other Cellular Therapy Donors\n\n* Donors are eligible to participate in the Research Sample Repository if they have donated or are scheduled to donate HCs or cellular therapy products to an allogeneic recipient either by a marrow harvest or by apheresis. This includes adults with and without decision making capacity and children.\n* All donors registered on the National Marrow Donor Program (NMDP) Registry, regardless of whether they have been requested to donate a product for a patient, are eligible to participate in the Research Sample Repository.\n\nCord Blood Units (CBUs)\n\n* Testable material from CBUs (Specimens) infused at treatment centers covered under the C. W. Bill Young Transplantation Program are eligible for inclusion in the Research Sample Repository. Material may be submitted by participating treatment centers, centralized laboratories and Cord Blood Banks.\n\nHematopoietic Cell Transplantation or Other Cellular Therapy Recipients\n\n* All U.S. recipients of allogeneic or autologous HC transplants or cellular therapies are eligible to participate in the Research Sample Repository. This includes adults with and without decision making capacity and children.\n\nPatients with Marrow Toxic Injury\n\n* Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Sample Repository. This includes adults with and without decision-making capacity and children.\n* Eligible patients may have received support care only, growth factor support, hematopoietic stem cell transplant or other appropriate medical treatment for marrow toxic injury",{"count":18,"type":19},"The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy.\n\nRepresentatives of participating centers and investigators or research groups may request access to research samples contained in the Research Sample Repository for the purpose of conducting research including:\n\n* investigating molecular explanations for histocompatibility or clinical outcomes through analysis of genomic, epigenetic, or other biomolecular data\n* evaluating the factors that affect transplant or cellular therapy outcome\n* studying the distribution of HLA tissue types in different populations\n* studying the success of transplantation, cellular therapies or supportive care in the management of marrow toxic injuries\n* performing de-linked (anonymous) research",[23,24,91,92],"Cellular Therapy","Marrow Toxic Injury","2023-05-01",{"date":95,"type":39},"2023-05-03",{"date":97,"type":39},"1991-07",{"date":99,"type":19},"2030-07",{"name":45,"class":46}]